AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 36 analysts
Fundamentals
Fundamentals institutional score is 90 using growth durability 90.3.
Valuation
Valuation institutional score is 3 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 44 using mean target upside 9.1%; dispersion penalty 20.6; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 58 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 20.6% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.3). Confidence: 80%.
Live forward EPS implies next-12-month EPS of ₹102.30. Applying the stock's normalized valuation corridor produces a fair range of ₹1,349.34 to ₹1,828.10, with base value near ₹1,659.31 (-27.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹102.30
Forward P/E
22.5x
Base Fair Value
₹1,659.31
Fair Range
₹1,349.34 - ₹1,828.10
Upside To Base
-27.9%
Estimate Source
Live forward EPS
Growth Estimate
+16.0%
5Y Average
12.06
Current
19.57
Overvalued
17.87
Undervalued
13.19
5Y Average
7.62
Current
12.03
Overvalued
10.75
Undervalued
4.06
5Y Average
2.22
Current
3.51
Overvalued
2.56
Undervalued
1.89
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.2x Undervalued | -29% vs avg | -2.7% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.7x Premium | +59% vs avg | +36.2% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.4x Undervalued | -28% vs avg | +11.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Undervalued | -24% vs avg | -15.6% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.4x Fair | 0% vs avg | +0.8% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +85% vs avg | +121.8% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.6x Undervalued | -22% vs avg | +31.7% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 29.2x Undervalued | -41% vs avg | -3.9% |
LUPIN LIMITED trades at a discount (19.0x vs peer avg 49.5x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CIPLA LTD, TORRENT PHARMACEUTICALS L, GLENMARK PHARMACEUTICALS — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹7.17K CrJun 2026Latest net profit
₹2.71K CrJun 2026Latest EPS
₹59.37Jun 2026Net margin
52.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,496 | 3,659 | 4,116 | 3,396 | 4,168 | 4,106 | 4,208 | 4,486 | 5,709 | 4,068 | 4,501 | 5,235 | 7,172 |
| Expenses + | 2,791 | 2,824 | 2,898 | 2,696 | 2,968 | 2,991 | 2,797 | 2,740 | 2,979 | 2,893 | 2,885 | 2,953 | 3,439 |
| Operating Profit | 705 | 835 | 1,217 | 700 | 1,200 | 1,115 | 1,411 | 1,746 | 2,730 | 1,176 | 1,617 | 2,282 | 3,733 |
| OPM % | 20% | 23% | 30% | 21% | 29% | 27% | 34% | 39% | 48% | 29% | 36% | 44% | 52% |
| Other Income + | 28 | 26 | 23 | 31 | 38 | 33 | -22 | 49 | 54 | 663 | -534 | 537 | 102 |
| Interest | 16 | 15 | 11 | 13 | 14 | 18 | 20 | 34 | 19 | 28 | 36 | 39 | 36 |
| Depreciation | 140 | 149 | 145 | 290 | 141 | 146 | 153 | 208 | 177 | 175 | 179 | 177 | 190 |
| Profit before tax | 577 | 696 | 1,084 | 428 | 1,083 | 984 | 1,217 | 1,553 | 2,588 | 1,636 | 868 | 2,602 | 3,610 |
| Tax % | 17% | 21% | 15% | 10% | 18% | 18% | 19% | 17% | 18% | 17% | 17% | 17% | 25% |
| Net Profit + | 477 | 549 | 916 | 384 | 889 | 808 | 985 | 1,291 | 2,128 | 1,357 | 717 | 2,164 | 2,715 |
| EPS in Rs | 10.48 | 12.05 | 20.13 | 8.43 | 19.50 | 17.71 | 21.58 | 28.28 | 46.60 | 29.72 | 15.71 | 47.33 | 59.37 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation